Infinity Pharmaceutical (INFI) RA Outcome As Expected, Says RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Infinity Pharmaceutical (INFI) RA Outcome As Expected, Says RBC
January 12, 2015 8:04 AM EST
Infinity Pharma (NASDAQ: INFI) announced its anticipated pipeline goals and provided financial guidance for 2015. Infinity anticipates that it will report top line data from DYNAMOTM, a Phase 2 study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma (iNHL), in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUOTM, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), in the second half of 2015. During the year, Infinity expects three company-sponsored clinical studies of... More
January 8, 2015 6:52 AM EST
Infinity Pharma (NASDAQ: INFI) announced that ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) did not meet its primary endpoint. The primary endpoint was the ACR20 response rate at 12 weeks, which is defined as the proportion of patients who achieve at... More
